IgA肾病中时变血尿与肾病进展的关联
该研究纳入1771例活检证实的IgA肾病患者,按血尿程度分组,采用边际结构模型评估时变血尿与复合肾脏结局的关联。中位随访48个月,487例(27.5%)发生主要结局。时变血尿≥100 RBC/μl与进展风险增加显著相关(HR 1.53,95%CI 1.14-2.06),在基线eGFR<60及蛋白尿≥0.5 g/d亚组中风险更显著。
要点
- 时变血尿≥100 RBC/μl与IgA肾病进展风险独立相关。
- 基线eGFR<60者中,时变血尿20-<100 RBC/μl亦与风险升高相关。
- 基线血尿经传统Cox模型未显示与结局显著相关。
核心结论
- 持续血尿≥100 RBC/μl可能作为IgA肾病风险分层标准,尤其在已有肾功能损害或蛋白尿未控制者中风险显著放大。
研究设计与样本
- 纳入1771例活检证实的IgA肾病患者,血尿按<10、10-<20、20-<100、≥100 RBC/μl分组。
- 采用传统Cox模型评估基线血尿,边际结构模型评估时变血尿,以控制时间依赖混杂。
主要发现
- 中位随访48个月,487例(27.5%)发生主要复合肾脏结局(eGFR下降40%或肾衰竭)。
- 时变血尿≥100 RBC/μl与主要结局风险增加相关(HR 1.53;95%CI 1.14-2.06)。
- 基线eGFR<60 ml/min/1.73m2亚组中,时变血尿20-<100 RBC/μl与风险升高相关(HR 1.89;95%CI 1.33-2.72)。
临床怎么用
- 对IgA肾病患者应动态监测血尿水平,持续≥100 RBC/μl提示进展风险增高。
- 基线eGFR<60或蛋白尿≥0.5 g/d者,即使中等程度时变血尿也需警惕进展风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Hematuria is a hallmark feature of IgA nephropathy (IgAN); however, its long-term impact on kidney outcomes remains incompletely characterized because of time-dependent confounding and lack of a standardized cutoff. This study evaluated the longitudinal association between hematuria and kidney disease progression. METHODS: We included 1771 participants with biopsy-proven IgAN. Hematuria was categorized into the following 4 groups: < 10, 10 to < 20, 20 to < 100, and ≥ 100 red blood cells (RBC)/μl. The primary outcome was a composite kidney outcome (40% estimated glomerular filtration rate [eGFR] decline or kidney failure). Conventional Cox proportional hazards models were used to assess baseline hematuria, whereas marginal structural models (MSMs) were employed to evaluate time-updated hematuria, accounting for time-dependent confounders and fluctuations in clinical parameters. RESULTS: During a median follow-up of 48 months, the primary outcome occurred in 487 (27.5%) participants. In the fully adjusted baseline Cox model, baseline hematuria was not significantly associated with the primary outcome. In contrast, MSMs revealed that time-updated hematuria ≥ 100 RBC/μl was significantly associated with an increased risk of progression (hazard ratio [HR]: 1.53; 95% confidence interval [CI]: 1.14-2.06). The adverse impact was particularly pronounced in subgroups with a baseline eGFR < 60 ml/min per 1.73 m2 and those with baseline proteinuria ≥ 0.5 g/d. Even moderate time-updated hematuria (20 to < 100 RBC/μl) was correlated with a substantially elevated risk (HR: 1.89; 95% CI: 1.33-2.72) in the subgroup with eGFR <60 ml/min per 1.73 m2. CONCLUSION: Our findings suggest that persistent hematuria ≥ 100 RBC/μl may serve as a valuable risk stratification standard, particularly given the significantly magnified risk in patients with pre-existing renal impairment or uncontrolled proteinuria.
引用
- Tang C, Si FL, Chen P, et al. Time-Updated Hematuria and Kidney Disease Progression in IgAN. Kidney Int Rep. 2026. PMID: 42471814. doi:10.1016/j.ekir.2026.106653
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。